口腔鳞癌新辅助化疗的回顾性研究

Retrospective Study of Neoadjuvant Chemotherapy in Operable Oral Cavity Cancer Patients.

目的 :探讨新辅助化疗在口腔鳞癌治疗中的近期和远期临床效果。方法 :对 1990 2 0 0 0年我院住院治疗的36例新辅助化疗口腔鳞癌患者和 72例术前未作任何辅助治疗的口腔鳞癌患者作回顾性分析 ,对化疗后临床肿瘤退缩程度、生存率、术后复发和转移率作比较。其中新辅助化疗组患者术前接受一个疗程的VM方案化疗后进行手术。结果 :新辅助化疗后临床完全缓解 6例 ,有 18例部分缓解 ,总有效率 6 6 .7%。在平均 4 8个月 (6 12 0个月 )的随访中 ,新辅助化疗组 12例出现复发 (33.3% )、3例 (8.3% )转移、6例 (16 .6 % )死于肿瘤 ,对照组 4 8例复发 (6 6 .7% ) ,2 0例 (2 7.8% )转移、2 8例 (38.9% )死于肿瘤 .两组差别有显著意义 (P <0 .0 5 )。结论 :新辅助化疗安全低毒、不影响手术、近期肿瘤缓解率明显、远期可减少术后复发和转移率。

Objective: To investigate the efficacy of neoadjuvant chemotherapy in operable oral cavity cancer patients. Methods: Ninty patients with operable oral cavity cancer were treated from 1990~2000. Thirty-six patients were initially treated with a mean of one cycle of VM as the neoadjuvant chemotherapy group.They were then subjected to surgery. Retrospective study includes clinical response of primary tumors and survival analysis. Results: Apartial response to preoperative chemotherapy was seen in 18 of 36 patitents. Follow-up for all patients ranges from 6~120 months (mean 48 months). Twelve patients in the neoadjuvant chemotherapy group(33.3%) and forty-eight patients in the control group(66.7%) developed a recurrence or metastasis ( P <0.05). Conclution: Oral cavity cancer patients with one cycle of VM neoadjuvant chemotherapy had better disease-free survival.